TA-ASSOCIATES
20.5.2020 08:02:07 CEST | Business Wire | Press release
Benson Oak Capital today announced that its private equity arm and co-investors have sold 100% of their stake in Klikpojisteni.cz, a.s. (“Klik”) to a company majority owned by TA Associates, a leading global growth private equity firm, and minority owned by MCI EuroVentures, a technology investment fund.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005971/en/
Klik operates a leading online insurance brokerage in the Czech Republic and Slovakia under domain names Klik.cz and Klik.sk, with offices in Prague, Usti nad Labem and Bratislava. It offers clients the ability to transparently compare prices for non-life and life insurance products, including MTPL, CASCO, home, travel and term life insurance. The company will continue to operate as a wholly-owned subsidiary under the Klik brand and under the leadership of its original founder Andrew Fuchs and management team, including Aleš Rothbarth and Lukaš Pikal, as it continues to innovate and provide high value to both insurers and policy-holders. The buyer of Klik also owns Netrisk, which operates Netrisk.hu and Biztositas.hu, two leading Hungarian online insurance brokerages. Klik.cz and Klik.sk will thus become key components of Central European Online Insurance Brokerage Group alongside netrisk.hu and Biztositas.hu.
Benson Oak and other investors funded Klik from its inception in 2011, and supported the company with multiple rounds of investment. Major Klik shareholders will become minority shareholders in the combined group, a sign of their continued commitment and belief in the team and the market.
Andrew Fuchs, Founder, CEO and Chairman of the board of Klik.cz and Klik.sk, said: “Klik has achieved a great deal since it was founded nine years ago, delivering impressive sales growth while consistently being the most innovative player in its local markets. I believe that the investment of a global private equity firm, such as TA Associates via Netrisk, is proof of the strength of our business and its continued importance in the Czech and Slovak insurance markets. Through the combination of our efforts and in partnership with a regional leader like Netrisk, I believe that we will be able to grow significantly in the coming years.”
Gabriel Eichler, the founder of Benson Oak, said: “We are very proud of what Klik has achieved, and pleased to have assisted in its evolution from a start-up to a leading brand in the burgeoning online insurance market in the region, employing over 120 people in the Czech Republic and Slovakia. Klik will have the opportunity to grow further and provide increasing value to its customers in partnership with Netrisk and under the leadership of TA Associates, one of the global leaders in growth private equity.”
Maxime Cancre, Senior Vice President at TA Associates, said: “We believe the combination of Klik and Netrisk creates a leading online insurance brokerage platform across three countries in the Central and Eastern European region, in line with TA’s strategy when we invested in Netrisk in January 2020. We are excited to bring Andrew Fuchs, the Klik team and the business into the Netrisk group.”
CORPIN served as financial advisers and Weinhold as legal advisers to the Sellers on the transaction.
About Klik.cz / Klik.sk
Klik.cz, founded in 2011, has become a leading online insurance brokerage company in the Czech Republic. In 2018, it entered Slovakia with Klik.sk. It offers clients the ability to transparently compare the prices for non-life insurance and life insurance products, including MTPL, CASCO, home, travel and term life insurance. Sites are www.klik.cz and www.klik.cz .
About Netrisk
Netrisk, founded in 1994, is the leading independent online insurance brokerage company in Hungary. In 2001, it became the first Hungarian company offering a platform for comparing and distributing insurance products via the internet. Today, Netrisk distributes several types of non-life insurance products, including MTPL, CASCO, home and travel insurance policies. In December 2019, Netrisk acquired one of its largest competitors, Biztositas.hu. More information can be found at netrisk.hu and Biztositas.hu.
About Benson Oak
Founded in 1991 by Mr. Gabriel Eichler, Benson Oak is the oldest investment banking boutique in the Czech and Slovak markets, advising clients on debt-raising and M&A transactions worth more than €6 billion. Benson Oak Capital has been investing in venture capital and private equity since 2001, with the mission to support entrepreneurs in building transformative businesses by funding deals as a lead investor and providing significant value-add. Investments include AVG Technologies, the first Central European company to IPO on the NYSE (in 2012), and Promo.com, a global leader in video marketing tools for SMBs. Its latest affiliated fund - Benson Oak Ventures - has an office in Tel Aviv and invests in early stage technology companies focused on B2C and SMB Tech on a global basis. More information can be found at www.bensonoakventures.com .
About TA Associates
TA Associates is a leading global growth private equity firm. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer and business services – TA invests in profitable, growing companies with opportunities for sustained growth, and has invested in more than 500 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $33.5 billion in capital since its founding in 1968 and is committing to new investments at the pace of over $2 billion per year. The firm’s more than 85 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. It has previously made investments in several companies in the Czech Republic, including AVG Technologies, a Czech cyber security company that TA invested in alongside Benson Oak; and W.A.G. payment solutions, a Czech provider of payment solutions for freight carriers in Europe and Turkey. More information about TA Associates can be found at www.ta.com .
About MCI
MCI is one of the largest technology investment funds in the region of Central and Eastern Europe, dedicated to digital private equity. MCI funds manage PLN 2.3 billion (EUR 550 million), investing capital in the areas of: pure-technology companies (disruptors), companies undergoing digital transformation and IT infrastructure. In over 20 years of history, the funds have carried out more than 100 investments and 60 exits. MCI aims at building regional digital champions. The Fund was involved in, among others, Mall.cz (e-commerce, Czech Republic), WP.pl (digital media, Poland), Invia (e-travel, CEE), Dotpay/eCard (fintech, Poland) and iZettle (fintech, global). More information about MCI can be found at www.mci.eu .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005971/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom